EssilorLuxottica has entered into an agreement to acquire Signifeye, a Belgian ophthalmology platform delivering high-quality patient care across 15 eye centers and clinics in the Flanders region. The transaction is expected to close by Q1 2026, subject to customary regulatory approvals and closing conditions.

The acquisition follows EssilorLuxottica’s recent purchase of Optegra, an integrated ophthalmology platform operating more than 70 clinics across the United Kingdom, Czech Republic, Poland, Slovakia and the Netherlands. According to EssilorLuxottica, the two transactions strengthen the company's medical presence in Europe while accelerating its evolution into a global med-tech leader.

Signifeye offers a comprehensive range of services, spanning ophthalmic treatments and elective vision procedures, enabling patients to access the full spectrum of eye healthcare under one platform. 

“With Signifeye joining EssilorLuxottica’s ecosystem, we strengthen our ability to deliver truly end-to-end eye care and redefine what medical excellence can be across the entire patient journey,” said Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer, EssilorLuxottica, in a joint statement. “By combining our medical and scientific innovation capabilities with Signifeye’s proven clinical excellence, we can meaningfully enhance the patient experience and empower people to live their best lives.”

“Joining forces with EssilorLuxottica and Optegra marks a transformative chapter for Signifeye," said Kathleen Moons, Chief Executive Officer of Signifeye. "By combining their global leadership in vision care with our commitment to patient care and clinical excellence, we look forward to building the future of eye care together.”